

1 HOGAN LOVELLS US LLP
2 Paul B. Salvaty (Bar No. 171507)
3 Stephanie K. Yonekura (Bar No. 187131)
4 Poopak Nourafchan (Bar No. 193379)
5 Samantha M. Kantor (Bar No. 275104)
6 1999 Avenue of the Stars, Suite 1400
7 Los Angeles, California 90067
8 Telephone: (310) 785-4600
9 Facsimile: (310) 785-4601
10 paul.salvaty@hoganlovells.com
11 stephanie.yonekura@hoganlovells.com
12 poopak.nourafchan@hoganlovells.com

13 Attorneys for Defendant
14 SAFRAN IDENTITY &
15 SECURITY, S.A.S (formerly known as Morpho
16 SAS)

17 UNITED STATES DISTRICT COURT
18 NORTHERN DISTRICT OF CALIFORNIA
19

20 UNITED STATES OF AMERICA and
21 STATE OF CALIFORNIA, *ex rel.*
22 VINCENT HASCOET and PHILIPPE
23 PACAUD DESBOIS,

24 Plaintiffs,

25 v.

26 MORPHO, S.A., a/k/a SAFRAN
27 IDENTITY & SECURITY, S.A., a
28 French Corporation; SAFRAN GROUP,
S.A., a French Corporation; and
SAFRAN U.S.A., INC.

Defendants.

Case No. 5:15-cv-00746-LHK

**DEFENDANT SAFRAN
IDENTITY & SECURITY, S.A.S's
REPLY IN SUPPORT OF
MOTION TO DISMISS THIRD
AMENDED COMPLAINT
PURSUANT TO FRCP 12(B)(1)
AND 12(B)(6)**

DATE: August 24, 2017
TIME: 1:30 p.m.
CTRM: 8

TABLE OF CONTENTS

		Page
1		
2		
3		
4	I. INTRODUCTION	1
5	II. RELATORS HAVE FAILED TO STATE A CLAIM FOR VIOLATIONS OF THE FALSE CLAIMS ACT	2
6	A. Relators Fail To Plead Fraud With Particularity As Required By Rule 9(b).....	2
7	1. The Particularity Requirements of Rule 9(b) Require More Than Mere “Notice” Of The Alleged Misconduct.	3
8	2. Generalized Allegations of a “Fraudulent Scheme” Do Not Satisfy Rule 9(b).	5
9	3. The TAC Contains No Allegation That Any Defendant Made Sales To The Government And Improperly Continues to Attribute Subsidiary’s Acts to Parent.....	6
10	4. Relators Continue to “Lump” All Defendants Together.	8
11	B. Relators Have Failed To Plead <i>Scienter</i> Under Rule 8(a).	9
12	III. RELATORS ARE NOT THE “ORIGINAL SOURCE” OF ANY FALSE CLAIM ALLEGATIONS RELATING TO THE DEFENDANTS.....	11
13	IV. RELATORS SHOULD NOT BE GIVEN LEAVE TO AMEND THE COMPLAINT.....	13
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		

TABLE OF AUTHORITIES

Page(s)

Cases

<i>Ashcroft v. Iqbal</i> , 556 U.S. 662 (2009)	9, 10, 11
<i>Bell Atl. Corp. v. Twombly</i> , 550 U.S. 550 (2007)	10, 11
<i>Bly–Magee v. Cal.</i> , 236 F.3d 1014 (9th Cir. 2001)	5
<i>Brown v. Carrington Mortg. Servs., LLC</i> , No. CV 12-6974 PA, 2013 WL 1196868 (C.D. Cal. Mar. 25, 2013)	13
<i>U.S. ex. rel. Cafasso v. Gen. Dynamics C4 Sys., Inc.</i> , 637 F.3d 1047 (9th Cir. 2011)	2, 5
<i>U.S. ex rel. Cericola v. Fed. Nat’l. Mortg. Assoc.</i> , 529 F. Supp. 2d 1139 (C.D. Cal. 2007)	1, 5, 6
<i>U.S. ex rel. Clausen v. Lab. Corp. of Am.</i> , 290 F.3d 1311 (11th Cir. 2002)	8
<i>Dole Food Co. v. Patrickson</i> , 538 U.S. 468 (2003)	7
<i>U.S. ex rel. Driscoll v. Spencer</i> , No. 13-17624, 2016 WL 4191896 (9th Cir. Aug. 9, 2016)	4, 5
<i>U.S. ex rel. Ebeid v. Lungwitz</i> , 616 F.3d 993 (9th Cir. 2010)	3, 5, 6
<i>Eclectic Properties East, LLC v. Marcus & Millichap Co.</i> , 751 F.3d 990 (9th Cir. 2014)	10
<i>U.S. ex rel. Escobar v. Universal Health Services</i> , 136 S. Ct. 1989 (2016)	4
<i>U.S. ex rel. Hartpence v. Kinetic Concepts, Inc.</i> , 792 F.3d 1121 (9th Cir. 2015)	13

1	<i>U.S. ex. Rel. Hendow v. Univ. of Phoenix,</i>	
2	461 F.3d 1166 (9th Cir. 2006).....	9
3	<i>U.S. ex rel. Hochman v. Nackman,</i>	
4	145 F.3d 1069 (9th Cir. 1998).....	9
5	<i>U.S. ex rel. Hockett v. Columbia/HCA Healthcare Corp.,</i>	
6	498 F. Supp. 2d 25 (D.D.C. 2007)	8
7	<i>U.S. ex rel. Hoggett v. Univ. of Phoenix,</i>	
8	No. 2:10-cv-02478-MCE-KJ, 2014 WL 3689764 (E.D. Cal. July 24,	
9	2014).....	12, 13
10	<i>U.S. ex rel. Hopper v. Anton,</i>	
11	91 F.3d 1261 (9th Cir. 1996)	9
12	<i>Katzir’s Floor and Home Design, Inc. v. M–MLS.com,</i>	
13	394 F.3d 1143 (9th Cir. 2004).....	7
14	<i>United States ex rel. Lee v. SmithKline Beecham, Inc.,</i>	
15	245 F.3d 1048 (9th Cir. 2001).....	5
16	<i>U.S. ex rel. McGrath v. Mircosemi Corp.,</i>	
17	140 F. Supp. 3d 885, 908 (D. Ariz. 2015).....	8, 10
18	<i>U.S. ex rel. Modglin v. DJO Global Inc.,</i>	
19	48 F. Supp. 3d 1362 (C.D. Cal. 2014).....	10, 11
20	<i>Neilson v. Union Bank of Cal.,</i>	
21	290 F.Supp.2d 1101 (C.D. Cal. 2003).....	7
22	<i>Owens v. Bank of Am., N.A.,</i>	
23	No. 11–cv–4580–YGR, 2013 WL 1820769 (N.D. Cal. Apr. 30, 2013)	11
24	<i>U.S. ex rel. Pecanic v. Sumitomo Elec. Interconnect Products, Inc.,</i>	
25	No. 2012-cv-0602-L (NLS), 2013 WL 774177 (S.D. Cal. Feb. 28, 2013).....	7, 8
26	<i>Romero v. Countrywide Bank, N.A.,</i>	
27	740 F. Supp. 2d 1129 (N.D. Cal. 2010).....	3
28	<i>S.E.C. v. Yuen,</i>	
	221 F.R.D. 631 (C.D. Cal. 2004)	1, 5
	<i>U.S. ex rel. Schaengold v. Memorial Health,</i>	
	No. 4:11-cv-58, 2014 WL 6908856 (S.D. Ga. Dec. 8, 2014)	8

1	<i>U.S. v. N. Am. Health Care, Inc.,</i>	
2	173 F. Supp. 3d 943 (N.D. Cal. 2016).....	12
3	<i>U.S. v. United Health Ins. Co.,</i>	
4	848 F.3d 1161 (9th Cir. 2016).....	5, 8, 9
5	<i>Zucco Partners, LLC v. Digimarc Corp.,</i>	
6	552 F.3d 981 (9th Cir. 2009).....	14
7	Statutes	
8	31 U.S.C. § 3729(b).....	9
9	Other Authorities	
10	Federal Rules of Civil Procedure	
11	Rule 8.....	10
12	Rule 8(a)	1, 9, 11, 13
13	Rule 9(b)	<i>passim</i>
14	Rule 12(b)(1)	12

I. INTRODUCTION

Defendants' moving papers showed the raft of shortcomings in Relators' Third Amended Complaint ("TAC") and described in detail the ways in which Relators have failed to correct the myriad of defects in their claims which this Court identified in its Order Granting Safran USA, Inc.'s Motion to Dismiss Second Amended Complaint (Dkt. #54).¹ Rather than meaningfully respond, Relators engage in diversionary bluster, presenting a lengthy discussion about the enactment and history of the FCA, making irrelevant assertions about Defendants' alleged failure to present "evidence" to support their Motion to Dismiss, and arguing legal "principles" that are contrary to settled Ninth Circuit law. Relators' Opposition serves only to highlight the woefully deficient state of the TAC and to establish the propriety of dismissing Relators' claims with prejudice and without leave to amend.

- **First**, Relators fail to show that they have satisfied the particularity requirements of Rule 9(b) or adequately pled *scienter* (or knowledge) under Rule 8(a). Although Relators admit Rule 9(b) requires them to plead the "who, what, when, where, and how" of an FCA claim with particularity (Opp. at 6:21-22), they point to nothing in the TAC that meets these requirements. Under Ninth Circuit law, Relators' vague and generalized allegations of a fraudulent "scheme" do not come close to satisfying the requirements of Rule 9(b). *See, e.g., S.E.C. v. Yuen*, 221 F.R.D. 631, 636-37 (C.D. Cal. 2004); *U.S. ex rel. Cericola v. Fed. Nat'l. Mortg. Assoc.*, 529 F. Supp. 2d 1139, 1142 (C.D. Cal. 2007).
- **Second**, Relators never grapple with the reality that the TAC alleges no facts to suggest that any Defendant submitted an actual false claim

¹ This Reply is being filed on behalf of Defendant Safran Identity & Security, S.A.S. (formerly known as Morpho SAS). Defendant Safran Identity & Security, S.A.S. was sold to a third party as of June 1, 2017, and is no longer an affiliate of Defendants Safran SA and Safran USA, Inc., who are now separately represented and will file a joinder, joining in this Reply.

to the government (or even to a “recipient of federal funds”) for payment. To the contrary, Relators appear to concede that the allegedly fraudulent sales were made ***not by Defendants, but by Defendants’ subsidiaries***. See Opp. at 12:17-20 (“the TAC pleads in detail that Defendants made sales through their subsidiaries.”). The Court already rejected Relators’ attempt to impute liability to Defendants based on a corporate affiliation. See Dkt. #54 at 15-16 (holding that “multiple courts have held that FCA claims cannot be imputed from one party to the other based purely on a parent-subsidiary relationship.”). Relators’ total failure (again) to plead facts showing that any Defendant actually submitted a false claim for payment to the government is fatal to the TAC. See, e.g., *U.S. ex. rel. Cafasso v. Gen. Dynamics C4 Sys., Inc.*, 637 F.3d 1047, 1055 (9th Cir. 2011).

- ***Third***, Relators fail to rebut Defendants’ showing that they do not qualify as original sources under the FCA. Because all of Relators’ allegations are lifted from public sources, they cannot prove their status as “original sources” of any allegations of fraud, which provides a separate and independent basis for dismissing the TAC.

Each of these flaws in the TAC is sufficient in itself to warrant dismissal of Relators’ claims with prejudice and without leave to amend.

II. RELATORS HAVE FAILED TO STATE A CLAIM FOR VIOLATIONS OF THE FALSE CLAIMS ACT

A. Relators Fail To Plead Fraud With Particularity As Required By Rule 9(b).

Relators make much of the fact that they were purported “insiders” who have “direct, firsthand, and independent knowledge” of information on which their FCA

claims are based. Opp. at 9-11. They have now had nearly two years to develop the facts of this case and to plead a viable “whistleblower” claim. As such, they should have no trouble meeting the heightened pleading standard applicable to their fraud claims and presenting this Court with at least *one example* of a false claim for payment that any defendant has submitted to the government, identifying at least *one individual* employed by a Defendant who was involved in this alleged fraud, and describing with *some modicum of specificity* when, where and how the purported fraud on the government allegedly occurred. They abjectly have failed to satisfy any of these requirements, despite numerous opportunities.

1. **The Particularity Requirements of Rule 9(b) Require More Than Mere “Notice” Of The Alleged Misconduct.**

As Defendants showed in their Motion, and as Relators acknowledge, Rule 9(b) requires a plaintiff to “identify the ‘who, what, when, where and how of the misconduct charge,’” as well as what is false or misleading about the purportedly fraudulent conduct, and why it is false.” Mot. at 8:22-27 (quoting *U.S. ex rel. Ebeid v. Lungwitz*, 616 F.3d 993, 998 (9th Cir. 2010)). And as this Court previously held, “an FCA plaintiff must allege, at the very least, ‘particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that [false] claims were actually submitted.’” Dkt. #54 at 12-13 citing *Ebeid*, 616 F. 3d at 998. Rule 9(b) also requires a plaintiff to “establish a complete causal relationship between the alleged misrepresentations and the harm claimed to have resulted therefrom.” *Romero v. Countrywide Bank, N.A.*, 740 F. Supp. 2d 1129, 1146 (N.D. Cal. 2010) (citation omitted).

Here, Relators do not explain what role, if any, each Defendant played in the alleged fraud, and instead continue to lump all of the Defendants together in every respect. Nor do Relators explain what role any of the individuals named in the TAC played in the contracting or sale of any products to the United States or California governments beyond the non-factual allegations that certain executives

1 visited the United States and were somehow “instrumental” to the government’s
 2 decision to enter contracts with non-parties.² Nor do Relators address, much less
 3 distinguish, the cases showing that the Ninth Circuit routinely dismisses FCA
 4 claims that fail to allege with particularity “who” made the alleged false
 5 misrepresentations, “when” the alleged misrepresentation occurred, “where” the
 6 misrepresentations were made, “what” the false claims were made, and whether the
 7 alleged misrepresentation was material to the government’s payment.

8 Instead, Relators argue that their allegations should be deemed sufficient
 9 because they need only to provide enough detail to “give the defendants notice of
 10 the particular misconduct . . . so that defendants can defend against the charge.”
 11 Opp. at 6:16-18. But whether Relators have satisfied the particularity requirements
 12 of Rule 9(b) does not depend on whether the TAC’s allegations are specific enough
 13 that Defendants can answer them.³ As recognized by Relators’ own authorities,

14
 15 ² In their Opposition, Relators also rely on *U.S. ex rel. Escobar v. Universal*
 16 *Health Services*, 136 S. Ct. 1989 (2016), for the proposition that when a defendant
 17 submits a claim for payment to the government, it impliedly certifies compliance
 18 with regulatory, statutory and contractual requirements, and non-compliance with
 19 any of those requirements renders the claim “false” even if defendant made no
 20 explicit false statement. Opp. at 3:21-27. In *Escobar*, the Supreme Court held that a
 21 misrepresentation about compliance with a statutory, regulatory, or contractual
 22 requirement must be **material** to the Government’s payment decision in order to be
 23 actionable under the FCA. 136 S. Ct. at 2001. It requires a showing that the
 24 government **actually would deny claims** if it knew about the violation, not just that
 the defendant violated a requirement designated as a condition of payment, or that
 the government has the option not to pay because of the violation. *Id.* at 2003. The
 plaintiff also must show that the defendant **knew**, through actual knowledge or the
 reasonable person standard, that the government would not pay the claim if
 informed of the violation. *Id.* at 2003-04. Here, Relators have not even alleged
 enough to bring *Escobar* into play because: (1) Relators have failed to allege any
 false claim, thus materiality cannot even be evaluated; and (2) as demonstrated in
 the Motion, software and technology can incorporate pieces of foreign software and
 technology and still be deemed to have been made in the United States. *See* Mot. at
 16:19-18:2.

25 ³ Relators rely on the unpublished case, *U.S. ex rel. Driscoll v. Spencer*, No.
 26 13-17624, 2016 WL 4191896 (Mem) (9th Cir. Aug. 9, 2016), for the proposition
 27 that they need only allege facts specific enough “to allow defendants to answer
 28 them and state a defense.” Opp. at 7:21-22:2. But the facts in *Driscoll* are
 inapposite. Unlike here, in *Driscoll*, the court found that the first amended
 complaint provided “several detailed, representative examples of [the] alleged
 misconduct,” including specific individuals who carried out the fraud, and specific
 dates on which the fraud occurred, by a relator who had personal knowledge of

1 while Relators’ allegations “may be sufficient” to enable a defendant to defend
 2 against a charge, they are insufficient to show the allegations against these
 3 defendants have a “factual basis,” which is necessary to pleading a viable claim
 4 under the FCA. *U.S. v. United Health Ins. Co.*, 848 F.3d 1161, 1182 (9th Cir.
 5 2016) (“Swoben”), *citing Bly–Magee v. Cal.*, 236 F.3d 1014, 1018-19 (9th Cir.
 6 2001). Here, as in *Swoben*, Relators provide no details whatsoever to link any
 7 particular Defendant to any fraudulent scheme or to explain what role any particular
 8 Defendant played in any alleged fraud. Their allegations are woefully deficient
 9 under Rule 9(b). *See Swoben*, 848 F. 3d at 1182 (holding that with respect to the
 10 allegations against defendants Aetna, WellPoint and Health Net, the complaint
 11 offers only broad allegations lacking particularized supporting details); *see also*
 12 *Cafasso*, 637 F.3d at 1057 (holding the complaint failed to satisfy Rule 9(b) where
 13 the allegations were lacking in detail); *United States ex rel. Lee v. SmithKline*
 14 *Beecham, Inc.*, 245 F.3d 1048, 1051 (9th Cir. 2001) (holding a “broad claim” with
 15 “no factual support” was insufficient to satisfy Rule 9(b)).

16 2. **Generalized Allegations of a “Fraudulent Scheme” Do Not** 17 **Satisfy Rule 9(b).**

18 Rather than plead fraud with particularity, Relators rely again on generalized
 19 allegations of an amorphous “fraudulent scheme.” Opp. at 6:11-15, *citing Ebeid*,
 20 161 F. 3d at 998-999. But controlling law precludes Relators from generally
 21 asserting a “complex fraudulent scheme” to “get around the stringent pleading
 22 requirements of 9(b).” *Yuen*, 221 F.R.D. at 636-37; *Cericola*, 529 F. Supp. 2d at
 23 1142 (motion to dismiss granted where allegations were “devoid of the requisite
 24 particularity required under the Rule 9(b) pleading standard” because complaint
 25 alleged “only a vague scheme to submit false claims to HUD to obtain insurance
 26 defendants’ practices because he was a part of defendants’ operation. *Driscoll*,
 27 2016 WL 419186, at *1. These examples, while not sufficient in themselves, were
 28 enough for the court to grant relator another opportunity to amend his complaint.
Id. No such specificity exists in the TAC here, nor do Relators identify any. Here,
 Relators have pled no claim, no detail and no specifics, and they have pled no facts
 to support any personal knowledge for Defendants’ practices.

1 reimbursement for non-qualifying loans.”).⁴

2 The Ninth Circuit’s decision in *Ebeid* refutes, rather than supports, Relators’
 3 position. In *Ebeid*, the Court held that, under Rule 9(b), a relator is not necessarily
 4 required to identify “representative examples of false claims to support every
 5 allegation,” but still must allege “*particular details of a scheme to submit false*
 6 *claims paired with reliable indicia that lead to a strong inference that claims were*
 7 *actually submitted.*” *Ebeid*, 616 F.3d at 998-999 (emphasis added). Even under
 8 this standard, “Rule 9(b) still requires [Relators] to plead the fraud with some level
 9 of specificity,” including “enough detail to give [Defendants] notice of the
 10 particular misconduct which is alleged to constitute the fraud,” as well as
 11 “reasonable indicia that false claims were actually submitted,” and this still includes
 12 pleading the “who, what, when, where, and how” of each Defendant’s allegedly
 13 false claims. *Id.* (emphasis added) (citation omitted). Relators’ allegations fail to
 14 satisfy this standard because, as in *Ebeid*, where the Ninth Circuit affirmed
 15 dismissal of the complaint for failure to plead fraud with particularity, Relators
 16 assert only vague conclusions, without alleging any facts as to what any Defendant
 17 supposedly did or as to the “who, what, when, where, and how” of any alleged false
 18 claim. *Id.* The total absence of these essential facts renders Relators’ FCA claim
 19 defective and subject to dismissal under Rule 9(b). *Ebeid*, 616 F.3d at 1000.

20 **3. The TAC Contains No Allegation That Any Defendant Made**
 21 **Sales To The Government And Improperly Continues to**
 22 **Attribute Subsidiary’s Acts to Parent.**

23 Notably, the TAC contains no allegation that any Defendant made any sales
 24 to the government, and by Relators’ own admission, at most, the TAC alleges only

25 _____
 26 ⁴ In reaching this conclusion, the Court noted that there was “absolutely no
 27 mention of any actual loans, or any specific description of types of loans, allegedly
 28 submitted to the government,” and that, as a result, the allegations amounted to
 nothing more than a conclusory assertion that Fannie Mae “must have been
 engaged in fraudulent activity” because it participated in the relevant market and
 the pertinent government program. *Cericola*, 529 F. Supp. 2d at 1146.

1 that “*Defendants made sales through their subsidiaries* Morpho Trak and Morpho
 2 Trust to... Lockheed Martin, who in turn sold Defendants’ equipment to the
 3 government.” Opp. at 12:17-20 (emphasis added); *see also* TAC ¶ 9 (“each Safran
 4 Defendant worked at the direction of Safran, S.A. and each other Safran Defendant,
 5 to injure the United States and the State of California,” acting “by and through their
 6 agents, subsidiaries, and managerial employees.”).⁵ Relators’ apparent admission
 7 that the named Defendants did not actually make any allegedly false claims is fatal
 8 to the TAC. This Court previously held that FCA claims cannot be imputed from
 9 one entity to another based purely on a parent-subsidary relationship, (Dkt. #54 at
 10 15-16), and also previously rejected Relators’ attempts to excuse their pleading
 11 shortcomings based on Defendants’ “complicated” corporate structure, holding that
 12 the “complicated nature of Safran Global’s corporate structure does not excuse the
 13 requirements of Rule 9(b).” Dkt. #54 at 17.

14 This Court’s holding is consistent with Ninth Circuit law, which makes clear
 15 that “[a] parent company is presumed to have an existence separate from its
 16 subsidiaries,” *Neilson v. Union Bank of Cal.*, 290 F.Supp.2d 1101, 1116 (C.D. Cal.
 17 2003), and that “[t]he mere fact of sole ownership and control does not eviscerate
 18 the separate corporate identity that is the foundation of corporate law.” *Katzir’s*
 19 *Floor and Home Design, Inc. v. M-MLS.com*, 394 F.3d 1143, 1149 (9th Cir. 2004)
 20 (citing *Dole Food Co. v. Patrickson*, 538 U.S. 468, 475 (2003)). Thus, in order to
 21 avoid dismissal of their FCA claims, Relators must allege with particularity that
 22 each entity played a role in the submission of a false claim or statement. *U.S. ex*
 23 *rel. Pecanic v. Sumitomo Elec. Interconnect Products, Inc.*, No. 2012-cv-0602-L
 24 (NLS), 2013 WL 774177, at *5 (S.D. Cal. Feb. 28, 2013) (dismissing relator’s FCA

25
 26 ⁵ Even assuming that, as Relators contend, in the “post-FERA” era (which was
 27 enacted May 20, 2009), sales to the **government’s** subcontractors or subsidiaries
 28 fall within the ambit of the FCA (Opp. at 12:9-16), this change in the law still does
 not allow an FCA claim to proceed against a **parent** based solely on the conduct of
 its **subsidiary**. *See* Opp. at 12:17-20 (“The TAC pleads in detail that Defendants
 made sales through their subsidiaries Morpho Trak and Morpho Trust...to
 Lockheed Martin, who in turn sold Defendants’ equipment to the government...”).

claim where he failed to properly allege parent corporation's role in the submission of false claims or statements); *U.S. ex rel. McGrath v. Mircosemi Corp.*, 140 F. Supp. 3d 885, 908 (D. Ariz. 2015). *See also U.S. ex rel. Hockett v. Columbia/HCA Healthcare Corp.*, 498 F. Supp. 2d 25, 59-60 (D.D.C. 2007) (holding that a parent corporation is not liable for its subsidiary's FCA violation). Because the TAC is devoid of any factual allegation that any particular Defendant actually submitted a false claim for payment or was directly involved in causing such a submission to occur, there is no actionable claim under the FCA. *U.S. ex rel. Schaengold v. Memorial Health*, No. 4:11-cv-58, 2014 WL 6908856 at *14 (S.D. Ga. Dec. 8, 2014), *citing U.S. ex rel. Clausen v. Lab. Corp. of Am.*, 290 F.3d 1311 (11th Cir. 2002).

4. Relators Continue to "Lump" All Defendants Together.

Relators also fail to address Defendants' argument that, despite this Court's prior admonition against "lumping," the TAC continues to do just that—it asserts only generalized allegations against all Defendants, treating them as a single mass and failing to plead any specific facts to suggest that any Defendant did anything wrong. Mot. at 10-13. Unable to rebut Defendants' arguments or case law, Relators instead cite to a single sentence in *Swoben* in order to prove that "lumping" of Defendants is allowed. They claim: "There is no flaw in a pleading, . . . where, as here, collective allegations are used to describe the actions of multiple defendants who are alleged to have engaged in *precisely the same conduct*." Opp. at 8:17-21 (emphasis added). But their reasoning does not apply because there are no factual allegations concerning any fraudulent conduct by any Defendant, let alone any factual allegations to suggest that all Defendants engaged in the same misconduct. Instead, Relators seek to hold all Defendants liable based purely on their corporate affiliations with other companies who are not named as defendants in the case and whose own role in the allegedly fraudulent scheme is also undefined. Each Defendant has a different connection to the non-defendants

1 MorphoTrust and MorphoTrak who appear to be the focus of Relators’ allegations,
 2 and no Defendant is alleged to have engaged in the same conduct as any other
 3 Defendant, whether fraudulent or otherwise. As with prior Ninth Circuit decisions,
 4 the *Swoben* Court recognized that “Rule 9(b) does not allow a complaint to merely
 5 lump multiple defendants together but requires plaintiffs to differentiate their
 6 allegations when suing more than one defendant and inform each defendant
 7 separately of the allegations surrounding his alleged participation in the fraud.”
 8 *Swoben*, 848 F.3d at 1184.

9 **B. Relators Have Failed To Plead *Scienter* Under Rule 8(a).**

10 Relators’ allegations also do not meet the “knowledge” requirement of the
 11 FCA, which defines “knowing” as having actual knowledge of information, or
 12 acting in either deliberate ignorance or reckless disregard of the information's truth
 13 or falsity. 31 U.S.C. § 3729(b). Congress amended the FCA to include this
 14 definition to make “firm . . . its intention that the act not punish honest mistakes or
 15 incorrect claims submitted through mere negligence.” *U.S. ex rel. Hochman v.*
 16 *Nackman*, 145 F.3d 1069, 1073 (9th Cir. 1998) (citation omitted). The Ninth
 17 Circuit has further elaborated on the “central importance of the *scienter* element to
 18 liability under the False Claims Act,” holding that “it must be an intentional,
 19 palpable lie,” and that “*scienter* (*i.e.*, with knowledge of the falsity and with intent
 20 to deceive) must exist.” *U.S. ex. Rel. Hendow v. Univ. of Phoenix*, 461 F.3d 1166,
 21 1171-72 (9th Cir. 2006), *citing U.S. ex rel. Hopper v. Anton*, 91 F.3d 1261, 1265
 22 (9th Cir. 1996).

23 While Rule 9(b) allows a plaintiff alleging fraud to plead knowledge
 24 generally, it does not give the plaintiff “license to evade the less rigid—though still
 25 operative—strictures of Rule 8,” which require pleading facts that give rise to a
 26 ***plausible*** claim for relief. *Ashcroft v. Iqbal*, 556 U.S. 662, 686-87 (2009).
 27 “Plausibility” requires more than “legal conclusions and threadbare recitals of a
 28 cause of action.” *Eclectic Properties East, LLC v. Marcus & Millichap Co.*, 751

1 F.3d 990, 998 (9th Cir. 2014) (quotation and citation omitted); *see also Iqbal*, 556
 2 U.S. at 678 (“[T]he tenet that a court must accept as true all of the allegations
 3 contained in a complaint is inapplicable to legal conclusions.”); *U.S. ex rel.*
 4 *Modglin v. DJO Global Inc.*, 48 F. Supp. 3d 1362, 1384 (C.D. Cal. 2014) (the court
 5 need not accept as true “unreasonable inferences or conclusory legal allegations
 6 cast in the form of factual allegations.”).

7 Relators’ failure to meet this pleading standard is evidenced by their
 8 unfounded contention that they have pled “their qui tam case with extraordinary
 9 particularity,” thus satisfying Rule 8. Opp. at 7:10-11; *see also* Opp. at 12:27-13:5,
 10 citing TAC ¶ 9. Apparently, Relators hope that a formulaic recitation of the
 11 knowledge element of an FCA violation (*see* TAC ¶¶ 9, 19, 23, 24, 29) is sufficient
 12 to meet the obligation to plead facts showing knowledge of fraud. It is not. The
 13 TAC must also allege facts—not labels or conclusions—sufficient to show that
 14 Defendants had knowledge that the claims or statements were false when
 15 submitted. *Bell Atl. Corp. v. Twombly*, 550 U.S. 550, 555 (2007) (“‘entitle[ment] to
 16 relief’ requires more than labels and conclusions, and a formulaic recitation of the
 17 elements of a cause of action will not do.”) (citation omitted). Here, Realtors’ non-
 18 factual allegation that Robert Eckel, the CEO of non-party MorphoTrust, made a
 19 “knowingly false” certification (TAC ¶ 29) is insufficient to plead falsity on the
 20 part of any Defendant.⁶ *See* Opp. at 13:9-12; *see also, e.g., McGrath*, 140 F. Supp.
 21 3d at 909 (scienter not sufficiently alleged where the complaint failed to identify a
 22 single employee of defendant who allegedly certified ITAR compliance, much less
 23 that that person knew of or recklessly disregarded the basis for Relator’s claim of
 24 ITAR violations). Although the knowledge or *scienter* element of a fraud claim
 25 need not be pleaded with particularity, it “must still be pleaded sufficiently to make

26
 27 ⁶ Although Relators name three Safran S.A. executives in the TAC, they do
 28 not allege that any of them played any role in the contracting or sale of any
 products to the government—instead, the executives allegedly failed to act by
 keeping “secret from representatives of the United States and the State of California
 the Russian origin of the subject fingerprint identification algorithms.” TAC ¶ 19.

entitlement to relief plausible.” *Modglin*, 48 F. Supp. 3d at 1388, 1406 (the lone allegation in the complaint that defendants “knew that they were falsely and/or fraudulently claiming reimbursement” is too conclusory to plead a plausible claim for relief under Rule 8(a), *Iqbal*, and *Twombly*). *See also Owens v. Bank of Am., N.A.*, No. 11–cv–4580–YGR, 2013 WL 1820769 at *4 (N.D. Cal. Apr. 30, 2013) (dismissing complaint and holding that “allegations that BANA ‘knew or should have known’ that its representations were false, and that it had no intention to perform, are conclusory and insufficient to state a plausible claim for fraud under the *Twombly* standard”). For these reasons, Relators’ allegations fail to meet the pleading requirements or Rule 8(a).

III. RELATORS ARE NOT THE “ORIGINAL SOURCE” OF ANY FALSE CLAIM ALLEGATIONS RELATING TO THE DEFENDANTS.

In their Motion, Defendants demonstrated that Relators are not the “original source” of any false claim relating to Defendants because Relators’ allegations against Defendants have been publicly disclosed on Defendants’ or other government websites. Mot. at 22-24. To support this argument, Defendants presented the Court with direct comparisons between the allegations in the TAC, and publicly available information on the Internet. Mot. at 23-24 (comparing for example, TAC ¶ 14 and RJN Ex. E; TAC ¶ 23 and RJN, Ex. F; TAC ¶ 28 and RJN Ex. H; TAC ¶ 29 and RJN, Ex. J; TAC ¶ 23, 25, 28 and RJN Exs. J, K; TAC ¶ 25 and RJN Ex. L; TAC ¶ 27 and RJN Ex. M).

Relators do not refute any of these points in their Opposition.⁷ They apparently concede that their central allegations concerning Defendants, the Lockheed Martin contract, the Bio-Key International contract, and the details of the Blanket Purchase Agreement between the Department of Justice and non-party

⁷ Relators did not file objections to Defendants’ Request for Judicial Notice or any of the exhibits therein. Instead, they improperly attempt to object to certain exhibits through their declarations, which go beyond the bounds of permissible evidence at the motion to dismiss stage. *See* Evidentiary Objections, filed concurrently herewith.

1 MorphoTrust, among other things, were all derived from publicly available sources.

2 The only allegedly non-public information that Relators claim to have
 3 “disclosed” is the existence of the Sagem-Papillon Agreement, which they contend
 4 “makes clear” that “the Morpho software is Russian technology.” TAC ¶ 20. This
 5 generic and conclusory allegation does not come close to establishing that Relators
 6 are the “original source” of information to support an FCA claim. To qualify as an
 7 “original source,” Relators would need to plead independent knowledge of facts
 8 directly connecting *each Defendant* to the Sagem-Papillon Agreement, connecting
 9 *each Defendant* to the manufacturing of fingerprint technology products, and
 10 connecting *each Defendant* to the sale of fingerprint identification products to
 11 governmental entities. Relators have satisfied none of these requirements.

12 Even in this fourth iteration of Relators’ complaint, the connection between
 13 Relators’ FCA claims and the Sagem-Papillon Agreement remains unclear,
 14 unexplained and entirely speculative. *See* FAC ¶¶ 18, 19, 21, 23-29; Mot. at 4:5-
 15 5:10. Notably, Relators admit that no Defendant directly entered into any contract
 16 with any government agency for the sale of fingerprint technology. *Opp.* at 12:17-
 17 23. And, the only allegations that non-parties MorphoTrak and MorphoTrust
 18 entered into contracts for fingerprint identification products, with Lockheed Martin
 19 and the Department of Justice, respectively, are pulled directly from public
 20 sources. Thus, Relators have failed to plead any fact that connects any named
 21 Defendant to any fraudulent statement, claim for payment, or even to a government
 22 contract, let alone to the Sagem-Papillon Agreement. Because all of the TAC’s
 23 “facts” relating to Defendants are publicly available, Relators’ claims against
 24 Defendants also are subject to dismissal for lack of subject matter jurisdiction under
 25 Rule 12(b)(1). *See, e.g., U.S. v. N. Am. Health Care, Inc.*, 173 F. Supp. 3d 943,
 26 949-50 (N.D. Cal. 2016); *U.S. ex rel. Hoggett v. Univ. of Phoenix*, No. 2:10-cv-
 27 02478-MCE-KJ, 2014 WL 3689764, at *10-11 (E.D. Cal. July 24, 2014).

28 Unable to deny that all of their allegations regarding Defendants are generic

1 in nature and were taken directly from public sources, Relators rely on *U.S. ex rel.*
 2 *Hartpence v. Kinetic Concepts, Inc.*, 792 F.3d 1121 (9th Cir. 2015), to argue that a
 3 relator need not have had a hand in the public disclosure of the fraud in order to
 4 qualify as an “original source.” Opp. at 8:23-9:14. But this reliance is misplaced
 5 for two reasons. First, *Hartpence* arguably only applies to cases filed prior to 2010.
 6 Second, even if its holding were applicable to this case, the Ninth Circuit still
 7 requires the relator to show that “he has direct and independent knowledge of the
 8 information on which the allegations in his court-filed complaint are based,” a
 9 standard which Relators have not met—and cannot meet—with respect to any
 10 Defendant. *Hartpence*, 792 F.3d at 1128.

11 12 **IV. RELATORS SHOULD NOT BE GIVEN LEAVE TO AMEND THE COMPLAINT**

13 The TAC should be dismissed with prejudice. In granting Safran USA,
 14 Inc.’s motion to dismiss, the Court previously held that Relators’ “failure to cure
 15 the deficiencies identified in this Order will result in a dismissal with prejudice of
 16 Relators’ deficient claims and deficient prayer for damages.” See Dkt. #54 at p. 24.
 17 Relators have had nearly two years to plead a valid claim for relief, yet the TAC
 18 still fails to identify a single false claim that Defendants submitted to the
 19 government for payment, lacks the particularity required under Rule 9(b), and fails
 20 to meet the plausibility requirement of Rule 8(a). The only allegations specific to
 21 Defendants were taken from public websites. Moreover, Relators have offered
 22 nothing to suggest that they possibly could cure the deficiencies in the TAC if given
 23 leave to amend (nor do they argue that leave to amend should be granted).
 24 Accordingly, the TAC should be dismissed with prejudice and without leave to
 25 amend. *Brown v. Carrington Mortg. Servs., LLC*, No. CV 12-6974 PA (MRWx),
 26 2013 WL 1196868, at *2-4 (C.D. Cal. Mar. 25, 2013) (granting defendant’s motion
 27 to dismiss fraud claim without leave to amend noting that after three complaints,
 28 the plaintiff failed “to meet the heightened pleading standard of Rule 9(b)” and did

1 not allege viable claims for relief); *see also Zucco Partners, LLC v. Digimarc Corp.*,
2 552 F.3d 981, 1007 (9th Cir. 2009) (“The fact that [plaintiff] failed to correct these
3 deficiencies in its Second Amended Complaint is a strong indication that the
4 plaintiffs have no additional facts to plead. . . . [I]t was clear that the plaintiffs had
5 made their best case and had been found wanting.”) (quotation and citation
6 omitted).

7
8 Dated: June 16, 2017

HOGAN LOVELLS US LLP

9
10 By: /s/ Paul B. Salvaty

11 Paul B. Salvaty
12 Stephanie K. Yonekura
13 Poopak Nourafchan
14 Attorneys for Defendant
15 Safran Identity & Security SAS,
16 (formerly known as Morpho SAS)
17
18
19
20
21
22
23
24
25
26
27
28